

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

DELAY IN PUBLICATION OF ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2018, POSTPONEMENT OF BOARD MEETING, SUSPENSION OF TRADING, AND DELAY IN DESPATCH FOR CIRCULAR OF SHARE CONSOLIDATION

Reference is made to the announcements of China Regenerative Medicine International Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) dated 15 March 2019 in relation to (1) the date of meeting (the “**Board Meeting**”) of the board (the “**Board**”) of directors of the Company for the purposes of considering and approving, among other matters, the final results of the Company and its subsidiaries for the year ended 31 December 2018 (the “**Results**”), and considering the payment of a dividend, if any; and (2) the propose share consolidation of the shares of the Company (the “**Share Consolidation**”).

DELAY IN PUBLICATION OF ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT

Pursuant to Rules 18.03, 18.48A and 18.49 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**GEM Listing Rules**”), the Company is required to announce the Results and despatch the annual report for the year ended 31 December 2018 (the “**Annual Report**”) not later than 31 March 2019, being 3 months after the date upon which the financial year ended.

The Board wishes to inform the shareholders of the Company that additional time is required for the auditors to complete the audit procedures, including but not limited to obtaining information on certain impairment loss on goodwill and intangible assets and finalise the

audited consolidated financial statements of the Group for the year ended 31 December 2018. Accordingly, there will be a delay in publication of the Results and despatch of the Annual Report. It is expected that the Results will be announced and the Annual Report will be despatched to the shareholders of the Company on or before 15 April 2019.

POSTPONEMENT OF BOARD MEETING

The date of the Board Meeting originally scheduled to be held on 27 March 2019 will be re-scheduled to a later date.

Further announcement will be published in due course to inform the shareholders of the Company on the date of the re-scheduled Board Meeting and the release of the Results. The Company will continue to use its best endeavors to despatch the Annual Report to the Shareholders as soon as possible.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended from 9:00 a.m. on 1 April 2019, and will remain suspended until the publication of the Results and despatch of the Annual Report.

DELAY IN DESPATCH OF CIRCULAR FOR SHARE CONSOLIDATION

As a result of the suspension of trading of the shares of the Company, the expected timetable for the implementation of the Share Consolidation will be revised, and the circular (the “**Circular**”) containing details of the Share Consolidation will not be despatched to the shareholders of the Company on or before 2 April 2019. Further announcement will be published in due course to inform the shareholders of the Company of the revised timetable to the Share Consolidation and the expected date of despatch of the Circular.

As at the date of this announcement, there is no inside information of the Company which need to be disclosed pursuant to the GEM Listing Rules.

By Order of the Board
China Regenerative Medicine International Limited
Ray Yip
Chairman and Executive Director

Hong Kong, 26 March 2019

As at the date of this announcement, the executive Directors are Dr. Ray Yip (Chairman) and Mr. Wang Xuejun (Chief Executive Officer); and the independent non-executive Directors are Mr. Chan Bing Woon, SBS, JP, Mr. Wong Yiu Kit Ernest and Dr. Fang Jun.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcement” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.